Optison (Perflutren)

Perflutren, the active ingredient in Optison, is a ultrasound contrast agent presented as a suspension for intravenous injection for diagnostic imaging use. It enhances echocardiographic imaging by providing microbubbles that increase ultrasound backscatter, aiding assessment of cardiac function.

GNH USA supplies Optison as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Optison is employed in cardiac imaging to improve visualization of cardiac structures and blood flow.

Contrast‑enhanced echocardiography: improves endocardial border delineation and assessment of ventricular function. Left ventricular opacification: provides clear visualization of the left ventricular cavity for accurate volume measurements. Detection of intracardiac shunts: enhances contrast between chambers to aid identification of right‑to‑left or left‑to‑right shunts.

Optison may be associated with a range of adverse reactions following intravenous administration.

Common Side Effects: - Transient headache - Nausea or mild vomiting - Flushing or warmth sensation - Mild hypotension - Back pain or chest discomfort - Dyspnea that resolves quickly

Serious or Rare Side Effects: - Severe allergic reaction or anaphylaxis - Cardiopulmonary arrest - Persistent hypotension requiring intervention - Acute pulmonary hypertension - Life‑threatening bronchospasm

Prior to administration, clinicians should observe specific safety measures.

Assess hypersensitivity: verify no known allergy to perflutren or formulation components. Monitor vital signs: observe blood pressure, heart rate, and oxygen saturation during and after injection. Use low mechanical‑index ultrasound settings: reduces microbubble destruction. Avoid in right‑to‑left cardiac shunts: risk of microbubble passage to systemic circulation. Restrict use in severe pulmonary hypertension: potential for hemodynamic instability. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Perflutren may interact with other agents that affect cardiovascular stability or imaging quality.

Major Interactions (Avoid): - Concurrent use of another ultrasound contrast agent. - Known hypersensitivity to perflutren or lipid components. - Administration with high‑dose vasodilators that may exacerbate hypotension.

Moderate Interactions (Monitor Closely): - Use with beta‑blockers or calcium channel blockers: monitor for additive blood pressure effects. - Combination with diuretics: observe for rapid volume shifts. - Co‑administration with agents that alter pulmonary vascular resistance.